Chromocell Therapeutics Corporation (CHRO)

USD 1.32

(0.76%)

Total Liabilities Summary of Chromocell Therapeutics Corporation

  • Chromocell Therapeutics Corporation's latest annual total liabilities in 2023 was 6.54 Million USD , up 73.89% from previous year.
  • Chromocell Therapeutics Corporation's latest quarterly total liabilities in 2024 Q2 was 2.78 Million USD , down -3.97% from previous quarter.
  • Chromocell Therapeutics Corporation reported annual total liabilities of 3.76 Million USD in 2022, up 2.21% from previous year.
  • Chromocell Therapeutics Corporation reported annual total liabilities of 3.68 Million USD in 2021, up 0.83% from previous year.
  • Chromocell Therapeutics Corporation reported quarterly total liabilities of 2.78 Million USD for 2024 Q2, down -3.97% from previous quarter.
  • Chromocell Therapeutics Corporation reported quarterly total liabilities of 6.54 Million USD for 2023 FY, up 73.89% from previous quarter.

Annual Total Liabilities Chart of Chromocell Therapeutics Corporation (2023 - 2020)

Historical Annual Total Liabilities of Chromocell Therapeutics Corporation (2023 - 2020)

Year Total Liabilities Total Liabilities Growth
2023 6.54 Million USD 73.89%
2022 3.76 Million USD 2.21%
2021 3.68 Million USD 0.83%
2020 3.64 Million USD 0.0%

Peer Total Liabilities Comparison of Chromocell Therapeutics Corporation

Name Total Liabilities Total Liabilities Difference
AIM ImmunoTech Inc. 9.14 Million USD 28.491%
Ampio Pharmaceuticals, Inc. 2.37 Million USD -175.292%
Armata Pharmaceuticals, Inc. 142.02 Million USD 95.395%
Actinium Pharmaceuticals, Inc. 45.06 Million USD 85.486%
Azitra, Inc. 2.2 Million USD -197.0%
Can-Fite BioPharma Ltd. 3.74 Million USD -74.611%
Calidi Biotherapeutics, Inc. 18.25 Million USD 64.167%
CEL-SCI Corporation 17.31 Million USD 62.22%
iBio, Inc. 7.41 Million USD 11.728%
Lineage Cell Therapeutics, Inc. 38.99 Million USD 83.227%
MAIA Biotechnology, Inc. 7.08 Million USD 7.736%
Matinas BioPharma Holdings, Inc. 46.33 Million USD 85.882%
Navidea Biopharmaceuticals, Inc. 12.51 Million USD 47.735%
NovaBay Pharmaceuticals, Inc. 5.72 Million USD -14.352%
NanoViricides, Inc. 1.35 Million USD -381.385%
Oragenics, Inc. 1.79 Million USD -263.753%
BiomX Inc. 55.07 Million USD 88.124%
BiomX Inc. 55.07 Million USD 88.124%
Protalix BioTherapeutics, Inc. 50.86 Million USD 87.141%
Palatin Technologies, Inc. 10.85 Million USD 39.736%
Scorpius Holdings, Inc. 22.74 Million USD 71.24%
Theriva Biologics, Inc. 20.51 Million USD 68.115%